Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $10.80 Consensus PT from Analysts

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $10.80.

Several equities analysts recently issued reports on SANA shares. Jefferies Financial Group started coverage on Sana Biotechnology in a report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a report on Tuesday, March 18th.

Sana Biotechnology Trading Down 5.4%

Shares of SANA traded down $0.15 during mid-day trading on Friday, hitting $2.61. The company's stock had a trading volume of 11,689,022 shares, compared to its average volume of 3,607,104. The firm has a 50-day simple moving average of $2.07 and a 200 day simple moving average of $2.34. The firm has a market capitalization of $588.50 million, a P/E ratio of -2.97 and a beta of 1.78. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.40.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.02. As a group, sell-side analysts predict that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in shares of Sana Biotechnology by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock valued at $5,206,000 after purchasing an additional 26,601 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Sana Biotechnology by 7.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,108,617 shares of the company's stock valued at $5,068,000 after purchasing an additional 219,498 shares during the period. Integral Health Asset Management LLC grew its position in shares of Sana Biotechnology by 11.1% in the fourth quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company's stock valued at $3,260,000 after purchasing an additional 200,000 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Sana Biotechnology by 44.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock valued at $2,538,000 after purchasing an additional 478,596 shares during the period. Finally, Boxer Capital Management LLC purchased a new stake in shares of Sana Biotechnology in the fourth quarter valued at $2,518,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.